Xu Wen, Ye Panpan, Li Zhaochun, Shi Junting, Wang Wei, Yao Ke
Eye Center, the Second Affiliated Hospital, Medical School, Zhejiang University, 310009, Hangzhou, China.
Mol Biol (Mosk). 2010 Jul-Aug;44(4):664-70.
Retinal neovascularization is one of the leading causes for complete blindness in a number of diseases around the world. Endostar, a recently introduced recombinant human endostatin, has been considered as one of the most valuable anti-angiogenic agents. In this study, we demonstrate that Endostar inhibits both the proliferation of the choroid-retinal endothelial cells through limiting the progression of the cell cycle and their migration. Furthermore, Endostar induces the expression of the pigment epithelial-derived factor (PEDF) and suppresses the expression of the vascular endothelial growth factor (VEGF) and the fibroblast growth factor (FGF). Endostar also reduces the expression of the inflammatory mediator tumor necrosis factor-alpha (TNF-alpha), matrix metalloproteinases (MMPs) and vascular cell adhesion molecule-1 (VCAM-1). These findings reveal an integrated role of Endostar in the program of retinal vascular control and highlight its significant potential for broad clinical application.
视网膜新生血管形成是全球多种疾病导致完全失明的主要原因之一。恩度(Endostar)是一种最近推出的重组人内皮抑素,被认为是最有价值的抗血管生成药物之一。在本研究中,我们证明恩度通过限制细胞周期进程来抑制脉络膜视网膜内皮细胞的增殖及其迁移。此外,恩度诱导色素上皮衍生因子(PEDF)的表达,并抑制血管内皮生长因子(VEGF)和成纤维细胞生长因子(FGF)的表达。恩度还降低炎症介质肿瘤坏死因子-α(TNF-α)、基质金属蛋白酶(MMPs)和血管细胞黏附分子-1(VCAM-1)的表达。这些发现揭示了恩度在视网膜血管控制程序中的综合作用,并突出了其在广泛临床应用中的巨大潜力。